CTI BioPharma Corp. (CTIC) said Thursday that it has completed a Type B, End-of-Phase-2a meeting with the U.S. Food and Drug Administration for the continued development of its investigational myelofibrosis treatment candidate, pacritinib.
from RTT - Biotech https://ift.tt/2ObyDWi
via IFTTT
No comments:
Post a Comment